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P346 – Difference in mean VAS reduction (Nimesulide ER - Diclofenac SR), with 95% CI
Product Nimesulide ER Diclofenac SR NIM - DIC 95% CI
N N LL UL
Mean VAS reduction 131 5.46 131 4.87 0.59 -0.091 1.284
and day 30. WOMAC OA index 3.1 was evaluated at enrollment
and end of therapy. Nimesulide ER was to be considered non-
inferior if the lower bound of 95% confidence interval (CI) for the
treatment difference (Test - Reference) in mean VAS reduction
for pain was less than 1 cm (clinically acceptable significant dif-
ference). Safety was evaluated by analyzing all reported clinical
and laboratory adverse events.
Results: In mITT analysis mean VAS reduction was 5.46 for
Nimesulide ER and 4.87 for Diclofenac SR. The treatment differ-
ence (Nimesulide ER - Diclofenac SR) in mean VAS reduction
was 0.59, with a lower bound 95% CI of -0.091, which was within
the pre-specified non-inferiority margin of 1 cm.
In both treatment arms statistically significant decrease in pain
was observed from baseline to 30 min after treatment, with
additional decrease occurring at subsequent hours on Day 1 and
during observations made on Day 15 and Day 30. On Day 1,
maximum pain relief was achieved after 12 h in both arms (45%
and 41% reduction from baseline for Willgo and Voveran SR,
respectively). The VAS scores obtained in the Willgo treatment
group were lower than that in the Voveran SR treatment group
at every assessment. Statistically significant lower scores were
observed at 8 h (Day 1) and Day 30 for Willgo group as compared
to the Voveran SR group (p<0.05).
No statistically significant difference was observed in the
WOMAC scores obtained in the two groups at baseline (66.57
for Willgo and 65.58 for Voveran SR). Both groups exhibited a
statistically significant decrease in WOMAC scores at the end of
the therapy. The Willgo group had a favorable reduction (56.1%)
compared with that of Voveran SR (50.3%). Both the study treat-
ment produced significant improvement in global assessment of
efficacy and tolerability as assessed by the investigators and the
patients.
Both treatments were well tolerated and the reported adverse
events were mild and transient in nature. No SAE was reported
in either treatment.
Conclusions: Based on the study results, it can be concluded
that Willgo® is non-inferior to Voveran SR® with regard to mean
VAS reduction of patient self assessed pain and has a compara-
ble tolerability profile to that of Voveran SR®.
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Purpose: Background: Symptoms are transcient and unpre-
dictable in HOA. In particular, we miss data on patients affected
by a recent exacerbation of their symptoms ("flare").
Aim of this study: To describe and compare the characteris-
tics of hand OA patients whose symptoms are flaring versus
"quiescent" HOA.
Methods: Prospective cross-sectional clinical study. A sample of
100 French rheumatologists and 100 general practitioners (GPs)
had to describe 2 HOA patients presenting consecutively: 1 with
a flare of symptoms, i.e. pain score ≥ 50 mm on a VAS and
functional index for hand OA score (FIHOA) ≥ 5, and 1 with
quiescent symptoms (pain < 50 mm and FIHOA < 5). Patients
were both gender, age ≥ 45 years, fulfilling the ACR criteria, and
were initially separated according to the level of symptoms. Data
collected: Doctors characteristics, patients demographic data and
HOA description. Statistics: descriptive: numbers (%) and mean
(SD).
Results: 169 doctors (aged 50 years, 69% men) described 316
patients of which 178 (56%) were in the "flare" and 44% in the
non-flare group. 83% were women, aged 66 (10) years, with a
BMI of 25 (4), 29% still professionally active. 60% had a familial
history of HOA (mother affected mostly), 95% of women were
menopaused (mean age (51). There was no difference between
the two groups with respect to these data. Conversely patients
in the flare group were more often affected by OA in another site
(84% vs 71%; p < 0.01, mostly knee OA [75%]). Thumb base OA
was more frequent in the flare group (82% vs 68%; p= 0.004).
Symptoms were more recent (mean duration since 1st symptom:
1(4) vs 5 (5) years. There was no difference regarding the %
of right vs left-handed, the overall prevalence (80% vs 77%)
of Heberden/Bouchard nodes, or their site prevalence (75%
Heberden, 52% Bouchard) and number (6 (4) in both groups).
FIHOA score averaged 12 (4) in the flare group vs 4 (1). All the
items of the FIHOA showed differences between the 2 groups.
Pain score rated 66 (9) mm in the "flare" group vs 30 (11) mm in
the non-flare group.
Conclusions: There are some differences between HOA pa-
tients whose symptoms flare and patients with a quiescent OA: a
shorter duration since 1st symptom, thumb base more frequently
affected, and a higher prevalence of OA at another site (knee).
A cut-off of 50 mm on a pain VAS could allow to select "flaring"
patients in clinical studies.
Acknowledgment: This study was supported by a grant from
Expanscience Laboratories (Courbevoie France)
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Purpose: Many individuals diagnosed with knee osteoarthritis
(OA) develop functional gait limitations, especially reduced walk-
ing speeds and limited knee motion during limb advancement.
The benefits of celecoxib in reducing joint inflammation and
symptoms associated with knee OA have been well described.
However, little is known about the effects of pain and stiffness re-
duction on walking function. The aim of this study was to measure
with clinically available tools common gait parameters, functional
walking performance, as well as perceived pain, stiffness, and
function before and during a short course of celecoxib.
Methods: Eight subjects with symptomatic knee OA, 2 males and
6 females, with a mean age of 59 years (range 46-70) completed
testing procedures at a physicians’ office in a large University
Medical School setting. Each subject attended a screening visit
where the diagnosis of knee OA was confirmed and VAS scores
after a 50 feet walk test were recorded. If a subject was on
regular doses of analgesic medication, VAS range was required
to be between 30 mm and 90 mm. If not on regular doses of
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analgesic medication, VAS range was required to be between
40 mm and 90 mm. Lastly, all subjects were required to have a
Body Mass Index < 35.
For this multiple baseline, repeated measures design, all sub-
jects were evaluated for 3 baseline visits at 2 week intervals.
At the third baseline visit, subjects were then given an 8-week
course of celecoxib (200 mg/d). Outcome measures continued
to be collected at 2 week intervals during the 8 week course
of medication. At each of the seven total visits, subjects com-
pleted the VAS version of the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain, stiffness and
function scales; performed three trials of the Timed Up and Go
Test (TUG); and walked 24 feet for five trials across a com-
puterized gait mat that recorded velocity, cadence, step length,
and double support time. Means from all tests were calcu-
lated for each visit. The baseline values were averaged to more
accurately assess function prior to beginning medication. This
baseline value and data from the four bi-weekly medication ses-
sions were entered into one-way repeated measures ANOVAs
to determine within-group differences for each of the dependent
variables (p = 0.05). Paired t-tests were employed for post hoc
analyses.
Results: Results of the ANOVA indicated that subjects signifi-
cantly increased walking velocity (p=.029) and cadence (p=.001),
with post hoc tests indicating significant differences from base-
line at week 8 for velocity and weeks 6 and 8 for cadence. While
modest improvements occurred in step lengths and double limb
support time, the differences were not statistically significant. All
subjects significantly improved on their TUG scores (p=.009) and
on all aspects of the WOMAC (function: p=.005, pain: p=.019,
stiffness: p=.001).
Conclusions: Walking velocities improved steadily during the
eight week course of celecoxib. We believe the faster walking
speeds resulted because subjects took more steps rather than
longer steps. The effect of the medication on reducing symptoms
of pain and stiffness may account for a greater freedom of limb
movement, whereby subjects could more freely advance their
lower limbs, take additional steps, and improve efficiency of their
walking.
In addition to symptomatic relief of pain and stiffness, subjects
improved in all aspects of their walking performance. These
positive findings also support the use of a clinically-based, in-
strumented gait analysis to determine the effectiveness of this
medication on walking function in individuals with knee OA.
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Purpose: Aim of this study has been the identification of a
treatment algorythm based on the proposal a new ankle chondral
lesion classification, that took in consideration the need to better
localize, understand and commonly relate the different chondral
lesions patterns, diagnosed on MRI and confirmed and treated
by ankle arthroscopy, both in the distal tibia and in the talar
dome. Last ten years dilemma in such lesions treatment has
focused on talus lesions staging, that, in our opinion represents
just the 2/3 of the problem, neglecting the thorough examination
of the distal tibia articular surface lesions.
Methods: Initially we needed to create a classification of carti-
lage ankle lesions in order to identify a common language both
for the diagnosis then the planning and treatment of the le-
sions.One of the main problems to solve was that of evaluating,
beyond the talus lesions, until now considered alone, the distal
tibia extremity lesions wich until now have been in impingement
classification. We therefore searched for the most adequate and
homogeneous classification to answer the needs of foot and an-
kle surgeons in daily practice, searching for common parameters
between MRI -CT- RDX - Arthroscopic findings
Results: The goal of the classification we have developed proved
to be very usefull in the planning of the correct corresponding
surgical treatment.
As reported in the lecterature early detection and treatment
facilitates better outcome.
This is not only confirmed by our study, but we have found that
talus lesion starting from ll degree is very often associated to
a minor tibial plafond lesion, often understimated, secondary to
microinstability or to axial malalignement that in our experience
has required an associated high tibial osteotomy.
Conclusions: The rationale of this classification consists in
giving each lesion a precise identification of position subdiving in
A tibia, B talus as main lesions, 1-2-3 medial third, medial, lateral
third, "a" tibia and "b" talus as secondary lesions (were present)
We felt that it was important to mantain the classification of
Berndt and harty with regards to the depth and the anatomo-
pathological lesions found.
For the staging of the lesions with the new classification the
following will be used:
es. grade A2blll to define a lesion that has main localization
the tibia, the medial position, secondary localization in the talus
dome and grading of the lesion lll.
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Purpose: Whole body vibration (WBV) has been proposed as
an effective exercise intervention because of its potential for
increasing force generating capacity in the lower limbs, and
a training effect on the neuromuscular system. Knee OA is
associated with decreased muscular strength and neuromuscular
function in the lower extremities. The aim of this study was to
evaluate whether WBV would be able to improve muscle function
of the lower extremities and balance and to improve the patients
pain and physical signs of knee OA. In addition two different
WBV devices were compared, one with vibration alone (VibMax)
and one with vibration combined with the demand of keeping the
body equilibrium during WBV (ViBrosFär).
Methods: 52 female patients with knee OA, fulfilling the ACR-
criteria, volunteered to participate in this study. Their mean age
was 60.5 years (SD 9.9) and their mean Body Mass Index
was 28.8 kg/m2 (SD 4.5). Patients with other chronic diseases
or artificial knee or hip joint were excluded from the study.
Before randomization, the proprioception (measured as knee
joint position sense, JPS and threshold to detection of a passive
movement, TDPM), ability to climb up and downstairs on time,
walking on time, standing balance on a force plate and isometric
muscle strength was measured. In addition the patients filled in
the SF-36 and WOMAC questionnaires. Patients randomized to
either ViBrosfär (balance plate with laterally vibration, 24 - 30
Hz, 1-2 mm amplitude, Vibrosfär, ProMedVi, Sweden) or VibMax
(stable plate with both laterally and vertical vibration, 25-30 Hz,
1 1/2-4 mm amplitude, Vibmax, Xendon, Sweden) exercised two
times per week for eight weeks. The exercise progression was
standardized and equal for both exercise groups. A third group
acted as control group.
Results: Baseline values of proprioception showed a total mean
for all three groups of JPS: 5.5° (SD 2.6°) and for TDPM: 2.6°
(SD 1.1°); total mean for all three groups for climbing six steps
